Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive Chemotherapy
Conditions
Interventions
Chidamide
Venetoclax
+1 more
Locations
1
China
Blood Hospital
Tianjin, Tianjin Municipality, China
Start Date
August 5, 2024
Primary Completion Date
December 30, 2027
Completion Date
December 30, 2027
Last Updated
August 3, 2025
NCT06285890
NCT06220162
NCT04065399
NCT06859424
NCT04628026
NCT06484062
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions